arrow
N

Nicola Fazio

irccs european institute of oncology (ieo)
H指数:59
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project

在IMAGene项目中开发并验证用于高危人群早期检测胰腺癌的流行病学风险评分

2026-05-200
PRE
Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database

意大利胃肠胰神经内分泌肿瘤的实世界表现与结局:全国Itanet前瞻性数据库的研究结果

2026-04-180
OAAI
Rate and risk factors of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer: a retrospective analysis from a referral center

晚期卵巢癌新辅助化疗期间静脉血栓栓塞的发生率及危险因素:一家转诊中心的回顾性分析

2026-04-030
PRE
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

神经内分泌肿瘤骨转移:一项关于自然史和管理的意大利全国性调查结果

2025-11-180
OAAI
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy

AIMN, ITANET, SIE 联合立场文件:关于肽受体放射性核素治疗期间神经内分泌肿瘤类癌综合征及其危象的识别、预防和管理的联合立场文件

2025-10-070
OA
Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract

神经内分泌肿瘤(NEN)中的争议:ENETS关于胃肠胰道G3分化良好的神经内分泌肿瘤患者治疗立场声明

2025-08-090
OAAI
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025-04-040
OAAI